|
Sign In to gain access to subscriptions and/or personal tools.
|
The silent sextet
Ian W Campbell
Department of Biological and Medical Sciences, University of St Andrews, Fife, camp{at}ianw40.freeserve.co.uk
Henry Purcell
Cardiology Royal Brompton Hospital, Sydney Street, London
References
- De Courten I., McCarty D., Zimmet P. Diagnosis: the Scale of the Problem and Future Risks. In: GA Hitman ed. Type 2 diabetes: Prediction, Prevention. J. Wiley, Chichester,1999,pp17-36.
- Reaven GM Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.[Abstract]
- Kaplan NM The deadly quartet, upper body obesity, glucose intolerance, hypertriglyceridaemia and hypertension. Arch Intern Med 1989;149: 1514-20.[Abstract/Free Full Text]
- Kopelman PG Obesity as a medical problem. Nature 2000;404:635-43.[Web of Science][Medline]
[Order article via Infotrieve]
- Bailey CJ Anti-diabetic drugs. Br J Cardiol 2000;7:350-60.
- Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Br Med J 2000;21:405-12.
- Campbell IW Need for intensive, early glycaemic control in patients with type 2 diabetes. Br J Cardiol 2000;7:625-31.
- Schmitz A., Vaeth M. Microalbuminuria: a major risk factor in non-insulin dependent diabetes: a 10-year follow-up study of 503 patients. Diabetic Med 1987;5:126-34.[Web of Science]
- Macleod JM, Lutale J., Marshall SM Albumin excretion and vascular death in NIDDM. Diabetologia 1995;38:610-16.[Web of Science][Medline]
[Order article via Infotrieve]
- Bakris GL, Williams M., Dworkin L. et al. Preserving renal function in adults with hypertension and diabetes: a consensus report. Am J Kid Dis 2000;36:646-61.[Web of Science][Medline]
[Order article via Infotrieve]
- Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society endorsed by the British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80 (suppl 2):S1-S29.[Free Full Text]
- Yki-Jarvinen H. Management of type 2 diabetes mellitus and cardiovascular risk. Lessons from intervention trials. Drugs 2000;60:975-83.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Haffner SM, Lehto S., Ronnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes mellitus and in non-diabetic subjects without prior myocardial infarction. N Eng J Med 1998;339:229-34.[Abstract/Free Full Text]
- Rubins HB, Robins S., Collins et al. For VA-HIT Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Eng J Med 1999;341: 410-18.[Abstract/Free Full Text]
- Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905-10.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Collaborative Group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001;357:89-95.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Rolka DB, Fagot-Campagna A., Narayan KWV. Aspirin use among adults with diabetes. Estimates from the Third National Health and Nutrition Examination Survey. Diabetes Care 2001;24:197-201.[Abstract/Free Full Text]
- Scottish Intercollegiate Guideline Network (SIGN). Anti-thrombotic therapy. A national clinical guideline. Edinburgh: SIGN: 1999.
- Sanmuganathan PS, Ghahramani P., Jackson PR et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001;85:265-71.[Abstract/Free Full Text]
- Stout RW Insulin and atheroma: 20-year perspective. Diabetes Care 1990;13:631-54.[Abstract]
- Campbell IW Type 2 diabetes mellitus: metabolic cardiology. Br J Cardiol 2000;7:253-4.
The British Journal of Diabetes & Vascular Disease, Vol. 1, No. 1,
3-6 (2001)
DOI: 10.1177/14746514010010010101
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Bottomley, A. J Palmer, R. Williams, J. Dormandy, and M. Massi-Benedetti
Review: PROactive 03: Pioglitazone, type 2 diabetes and reducing macrovascular events -- economic implications?
The British Journal of Diabetes & Vascular Disease,
March 1, 2006;
6(2):
63 - 70.
[Abstract]
[PDF]
|
|
|
|
|
|
|
I. W Campbell
Pioglitazone -- an oral antidiabetic agent and metabolic syndrome modulator. Can theory translate into practice?
The British Journal of Diabetes & Vascular Disease,
July 1, 2005;
5(4):
209 - 216.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. Richardson and D. Kerr
Obesity in type 2 diabetes -- local experience in a district general hospital
The British Journal of Diabetes & Vascular Disease,
January 1, 2003;
3(1):
49 - 52.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Stott
Quality driven management of tablet-treated type 2 diabetes -- potential increases in GP practice prescribing costs
The British Journal of Diabetes & Vascular Disease,
January 1, 2003;
3(1):
64 - 68.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Grant
Preparing for the NSF -- educational opportunities
The British Journal of Diabetes & Vascular Disease,
November 1, 2001;
1(2):
142 - 142.
[PDF]
|
|
|
|
|
